Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blue Wolf Capital Partners
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Blue Wolf Capital Partners serves as a private equity sponsor and platform builder, recently acquiring seven European pharmaceutical manufacturing facilities from Recipharm and planning to combine them with Synerlab’s CDMO operations to form a major independent CDMO platform serving over 120 customers and maintaining a track record of quality and regulatory compliance [3][6].
- Modalities
- Small moleculeOral solid dosageSemi-solid dosageLiquid dosage
- Industry
- Investors
02
Partnerships
Recipharm (asset purchase)Synerlab (pending acquisition and platform formation)
Beyond the preview
Go deeper on Blue Wolf Capital Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blue Wolf Capital Partners.